Clazakizumab

Drug Profile

Clazakizumab

Alternative Names: ALD 518; ALD518-003; BMS-645429; BMS-945429

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis; Rheumatoid arthritis
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • No development reported Crohn's disease; Graft-versus-host disease

Most Recent Events

  • 06 May 2016 Clazakizumab licensed to Vitaeris worldwide
  • 23 Feb 2016 Alder Biopharmaceuticals has patent protection for clazakizumab in USA (Alder Biopharmaceuticals, Form 10-K, February 2016)
  • 24 Jun 2015 Phase II development for Psoriatic arthritis and Rheumatoid arthritis is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top